CIBC Private Wealth Group LLC Acquires 152 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

CIBC Private Wealth Group LLC increased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 48.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 463 shares of the company’s stock after purchasing an additional 152 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Prestige Consumer Healthcare were worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of PBH. Kestra Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth about $27,000. GAMMA Investing LLC boosted its position in Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after acquiring an additional 220 shares in the last quarter. Blue Trust Inc. boosted its position in Prestige Consumer Healthcare by 24.8% during the 4th quarter. Blue Trust Inc. now owns 2,190 shares of the company’s stock valued at $158,000 after acquiring an additional 435 shares in the last quarter. KBC Group NV boosted its position in Prestige Consumer Healthcare by 28.3% during the 4th quarter. KBC Group NV now owns 2,048 shares of the company’s stock valued at $160,000 after acquiring an additional 452 shares in the last quarter. Finally, Longboard Asset Management LP bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $201,000. 99.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

PBH has been the subject of a number of recent analyst reports. StockNews.com lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday. Royal Bank of Canada boosted their target price on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research note on Friday, March 21st. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group boosted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $93.33.

Prestige Consumer Healthcare Trading Up 4.4 %

NYSE:PBH opened at $83.35 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 19.52, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The business has a fifty day moving average price of $84.33 and a 200-day moving average price of $79.69.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.